登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《LANCET，4月3日，Baricitinib for COVID-19: a suitable treatment?》

  • 来源专题：COVID-19科研动态监测
  • 编译者： xuwenwhlib
  • 发布时间：2020-04-04

  • Baricitinib for COVID-19: a suitable treatment?

    Ennio G Favalli，Martina Biggioggero，Gabriella Maioli，Roberto Caporali

    Published:April 03, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30262-0

    As rheumatologists used to treating rheumatoid arthritis with Janus kinase (JAK) inhibitors and working in an area (Lombardy, Italy) with a high incidence of coronavirus disease 2019 (COVID-19), we read with great interest the Comment in The Lancet Infectious Diseases by Justin Stebbing and colleagues1 about the potential use of baricitinib for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The described mechanism affecting viral endocytosis mediated by two members of the numb-associated kinase family is one of the many unfamiliar effects of a relatively recent drug class, the real safety profile of which still remains to be definitively clarified. Undoubtedly, the fact that baricitinib can provide this antiviral effect at the approved dose for rheumatoid arthritis therapy is an undeniable advantage over other potential inhibitors of the same pathway.

  • 原文来源：https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30262-0/fulltext
44浏览量
原文链接
相关报告

  • 《LANCET，4月3日，Baricitinib for COVID-19: a suitable treatment? – Authors' reply》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-04
    • Baricitinib for COVID-19: a suitable treatment? – Authors' reply Peter J Richardson，Mario Corbellino，Justin Stebbing Published:April 03, 2020DOI:https://doi.org/10.1016/S1473-3099(20)30270-X We thank Ennio Favalli and colleagues for their Correspondence regarding our suggestion to use baricitinib for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.1, 2 We also appreciate their recognition that inhibition of numb-associated kinase enzymes could indeed be beneficial in preventing virus infectivity via inhibition of clathrin-mediated endocytosis. We welcome the opportunity to more fully explain the possible use of baricitinib in the current pandemic. Indeed, we accept that using a JAK1 and JAK2 inhibitor to treat a viral disease might appear illogical given that the antiviral effects of interferons are largely mediated by the JAK–STAT signalling pathway. However, the administration of pegylated-interferon has not had the beneficial antiviral effects originally hoped for,4 and clinical trials with interferons have yielded inconsistent results, with pathogenic effects of interferons being observed in some viral infections.
    91浏览量
    原文链接

  • 《LANCET，4月3日，Preparing African anticancer centres in the COVID-19 outbreak》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-04
    • Preparing African anticancer centres in the COVID-19 outbreak Amine Souadka，Amine Benkabbou，Brahim Al Ahmadi，Saber Boutayeb，Mohammed，Anass Majbar Published:April 03, 2020DOI:https://doi.org/10.1016/S1470-2045(20)30216-3 We congratulate Wenhua Liang and colleagues for their Comment laying out the strategic policies against cancer during the COVID-19 outbreak.1 The disease is now spreading rapidly to and within Africa. Like other countries, Morocco had the opportunity to analyse early COVID-19 data and acknowledge that individual-scale policies such as isolation would not stop the pandemic. Morocco adopted large-scale drastic measures early, including constraining mobility with a mandatory restrictive housing and curfew, despite the low number of cases (starting from 60 cases) compared with Europe. We expect that COVID-19 will have a major impact on African countries, with the risk of a rapid health-care system shutdown, due to a pre-existing shortage in material (eg, intensive-care unit beds or protective equipment) and human resources.
    112浏览量
    原文链接